Markets are beset by volatility, with unpredictable swings making recent sessions something of a roller coaster. The main indexes were falling sharply at the end of last week, but Friday’s release of economic data showing strong manufacturing activity provided a boost that pared back the market losses somewhat. The recent earnings season also gave reason for optimism – the S&P listed companies, collectively, reported 46% year-over-year earnings gains in Q1, compared to the 20% expected. Goldman Sachs strategist David Kostin sees the generally positive macro data providing support for equities in an uncertain market environment. “The combination of global reopening, elevated consumer savings, and strong corporate operating leverage will drive sharp recoveries in both economic and earnings growth… U.S. equities will continue to appreciate, albeit at a slower pace than has characterized the past 12 months… equities will remain attractive relative to cash and bonds,” Kostin noted. Taking this into consideration, our attention turned to three stocks that Goldman Sachs thinks have outsized growth prospects, with the firm’s analysts forecasting over 100% upside potential for each. Using TipRanks’ database, we found out that the rest of the Street is also on board, as each boasts a “Strong Buy” consensus rating. Rain Therapeutics (RAIN) We’ll start with a newly public biopharmaceutical company Rain Therapeutics. The company is developing a tumor-agnostic treatment strategy that selects patients based on the underlying genetics rather than the histology of the disease. Rain has two drug candidates in the pipeline, RAIN-32, which is undergoing several clinical trials, and RAD52, which is still in preclinical trial. Taking a closer look at the pipeline, we find that RAIN-32, an MDM2 inhibitor called milademetan, has a Phase 3 trial for WD/DD liposarcoma scheduled to begin in the second half of this year. At the same time, a Phase 2 trial, an MDM2 basket study, is also scheduled for 2H21. Beyond the WD/DD Phase 3 and the Phase 2 Basket study, the company is also looking to initiate another Phase 2 study in intimal sarcoma by early 2022. RAD52, the company’s second pipeline candidate, is a novel approach to the treatment of breast, prostate, pancreatic, and ovarian cancers. The drug is still in early research phases, but lead candidate selection for clinical studies is set to begin sometime next year. As mentioned above, Rain is a newly public company; it held its IPO in April of this year. The company put 7,352,941 shares on the American public markets, at $17 each. The IPO raised about $125 million in gross proceeds. Opening coverage of this stock for Goldman Sachs, analyst Graig Suvannavejh writes: “While we’re optimistic on RAIN-32’s prospects in LPS, the revenue opportunity appears modest, as we project peak risk-unadj./adj. sales of $612mn/$428mn (assumes 70% POS), given just c.3K in US annual incidence. That said, our enthusiasm for RAIN also rests on RAIN-32’s potential beyond LPS, including in intimal sarcoma (an ultra orphan cancer), and also MDM2-amplified solid tumors, which we see as a substantial market opportunity. Across these three, we project $2.2bn/$859mn in peak yr risk unadj./adj. sales in the US/EU5, with other future indications for RAIN-32 (trials to start in 2022) and also a preclinical RAD52 program (a synthetic lethality play) representing upside potential to our forecasts.” In line with his bullish stance, Suvannavejh rates RAIN a Buy, and his $56 price target implies room for a stunning 252% upside potential in the next 12 months. (To watch Suvannavejh’s track record, click here) Turning now to the rest of the Street, other analysts echo Suvannavejh’s sentiment. As only Buy recommendations have been published in the last three months, RAIN earns a Strong Buy analyst consensus. With the average price target clocking in at $33.75, shares could soar 112% from current levels. (See RAIN stock analysis on TipRanks) Relmada Therapeutics (RLMD) The next stock on Goldman Sachs’s radar, Relmada Therapeutics, is a clinical-stage pharmaceutical firm, which focuses on issues of the central nervous system. REL-1017, the company’s prime pipeline candidate, is a novel NMDA receptor channel blocker under development as a treatment for major depressive disorder. Mental health is a major segment of the pharmaceutical industry, and the antidepressant piece of the mental health pie is expected to exceed $18.5 billion by 2027. Relmada started RELIANCE I, the first pivotal trial of REL-1017, in December of last year, testing the drug as an adjunctive treatment for major depression. By this past April, two additional studies, RELIANCE II and RELIANCE-OPS were underway. All three are now ongoing, and a fourth, Phase 1, study of REL-1017 as a monotherapy is set to begin in the first half of this year. Top-line data from the two pivotal studies is scheduled for release in 1H22. Goldman Sachs analyst Andrea Tan covers this stock, and she gives it a Buy rating along with a $78 price target that implies a 103% upside over the next 12 months. (To watch Tan’s track record, click here) “We note a string of key events in 2021+ that could drive value inflection: (1) human abuse potential (HAP) study against positive control oxycodone in 2Q21 and ketamine in 2H21, where we see the market as pricing in too much risk of a negative outcome (see scenario analysis within); (2) topline data for monotherapy REL-1017 in 4Q21; and (3) topline pivotal data in adjunctive MDD (GSe peak sales of $2.5bn in 2033) in 1H22 with NDA submission to follow thereafter, all of which we are constructive on given the differentiated profile demonstrating rapid onset of action, enhanced efficacy, and good tolerability to-date,” Tan opined. What does the rest of the Street have to say? 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $67.67 average price target, shares could climb 76% in the year ahead. (See RLMD stock analysis at TipRanks) Agiliti (AGTI) We’ll close out our look at high-potential Goldman picks with Agiliti. The company is a provider of medical equipment, offering hospitals and health systems a range of bariatrics, beds, therapy mattresses, fall prevention devices, ventilators, breast pumps, patient monitors, medical-grade adjustable chairs, and surgical equipment – along with the technical support, clinical engineering, and on-site management to properly use, maintain, and adjust the myriad devices. By the numbers, Agiliti boasts over 90 service centers across the lower 48 states, supporting more than 800,000 pieces of medical equipment in over 7,000 acute care hospitals and alternate medical sites. On April 23 of this year, Agility debuted its stock on the NYSE in an IPO that was initially priced at $14. The company put over 26.3 million shares on the market, and raised approximately $431.5 million in gross proceeds in the first day of the IPO. Last week, Agiliti released its first quarterly financial report as a public company. The top line revenue, at $235 million, was 31% higher than the year-ago Q1. Net income was $9.6 million, up a strong $22.2 million from last year’s Q1 net loss, and EPS was 9 cents per share. Looking at the company’
s forward path, Goldman Sachs analyst Amit Hazan noted, “While not reflected in the 1Q close balance sheet, management provided visibility to post-IPO leverage of approximately 3.3x on a pro-forma basis. While somewhat constrained from a managerial standpoint given demands from Northfield, management expects both the financial and managerial flexibility to pursue opportunistic M&A by later this year.” Hazan summed up, “We view AGTI’s end-to-end service model as differentiated and ideally suited in today’s Hospital operating environment; we see current valuation as an attractive entry point…” To this end, Hazan gives AGTI shares a Buy rating, and his $43 price target implies a 151% upside for the coming year. (To watch Hazan’s track record, click here) In its first few weeks on the public markets, AGTI shares have picked up 9 reviews, which include 8 Buys and just 1 Hold. The stock is selling for $17.12 and the $21.39 average price target suggests it has room for ~25% one-year upside potential. (See AGTI stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.